Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer

Background: S-1, a novel oral fluoropyrimidine, is well tolerated in patients with metastatic colorectal cancer (mCRC). The response rate of S-1 for colorectal cancer is high, ranging from 35% to 40%. This study aimed to evaluate the safety and efficacy of S-1 combined with oral leucovorin (LV) to e...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Koizumi, W., Boku, N., Yamaguchi, K., Miyata, Y., Sawaki, A., Kato, T., Toh, Y., Hyodo, I., Nishina, T., Furuhata, T., Miyashita, K., Okada, Y.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2010
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2844944/
https://ncbi.nlm.nih.gov/pubmed/19828562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdp371
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak